1
Country: USA | Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
2
Country: USA | Funding: $569.1M
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
3
Country: USA | Funding: $115.9M
Nurx is offering Truvada as "PrEP," or an HIV preexposure prophylaxis. People looking to get on PrEP can sign up via Nurx's website or smartphone app.
Nurx is offering Truvada as "PrEP," or an HIV preexposure prophylaxis. People looking to get on PrEP can sign up via Nurx's website or smartphone app.
4
Country: USA | Funding: $100M
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
5
Country: USA | Funding: $34.8M
Aethlon Medical creates immunotherapeutic devices to combat infectious disease and cancer.
Aethlon Medical creates immunotherapeutic devices to combat infectious disease and cancer.
6
Country: Germany | Funding: €301.4K
ImmunoLogik has identified an active agent that helps patients who have developed a resistance against standard HIV treatment therapies.
ImmunoLogik has identified an active agent that helps patients who have developed a resistance against standard HIV treatment therapies.
